Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Japanese Journal of Radiology|June 28, 2018
99mTc-GSA SPECT/CT fusion imaging for hepatectomy candidates with extremely deteriorated ICG valueTatsuaki Sumiyoshi, Takehiro Okabayashi, Yuji Negoro, et al.
Modern Rheumatology|December 5, 2006
A case of mixed connective tissue disease presenting with nephrotic syndromeHiro Kuroda, Keita Ishii, Yuji Negoro, et al.
Surgical Case Reports|March 5, 2016
Epiploic gonadal vein as a new bypass route for extrahepatic portal venous obstruction: report of a caseTatsuaki Sumiyoshi, Yasuo Shima, Takehiro Okabayashi, et al.
World Journal of Surgery|March 8, 2018
Chemoradiotherapy for Initially Unresectable Locally Advanced CholangiocarcinomaTatsuaki Sumiyoshi, Yasuo Shima, Takehiro Okabayashi, et al.
Japanese Journal of Radiology|October 18, 2017
A novel utility of 99mTc-GSA SPECT/CT fusion imaging: detection of inadequate portal vein embolizationTatsuaki Sumiyoshi, Yasuo Shima, Takehiro Okabayashi, et al.
Internal Medicine (Tokyo, Japan)|February 14, 2003
Limy bile syndrome complicated with primary hyperparathyroidismYuji Takatori, Kazuhiko Yamauchi, Yuji Negoro, et al.
Journal of Gastroenterology|December 6, 2018
Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical CancerDaisuke Hashimoto, Kota Arima, Shigeki Nakagawa, et al.
International Journal of Clinical Oncology|February 1, 2025
A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancerKoji Ando, Hironaga Satake, Mototsugu Shimokawa, et al.
Targeted Oncology|October 25, 2017
CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal CancerYu Sunakawa, Akihito Tsuji, Tadamichi Denda, et al.
International Journal of Clinical Oncology|May 31, 2019
Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)Nobuaki Suzuki, Shoichi Hazama, Takeshi Nagasaka, et al.
Pageof 3